Investor Presentation

Ref: AHCL/2026-27/C032 August 04, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 Scrip Code – 544350 Symbol : AGARWALEYE Dear Sir / Madam, Sub: Analyst / Earnings Conference Call - Presentation Ref: Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to the captioned subject, reference and our letter dated July 28, 2026, we enclose herewith, the presentation on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, to be made at the Analyst / Earnings conference call scheduled today, i.e. August 04, 2026 at 05:30 P.M. IST. The details of the aforesaid call and the presentation are also available on the website of the Company at: https://dragarwals.co.in/dr-agarwals-health-care/#analyst-earnings-call. We request you to kindly take the above on record. For Dr. Agarwal’s Health Care Limited Thanikainathan Arumugam Company Secretary and Compliance Officer Encl.: as above. DR. AGARWAL’S Kollam NNeehhrruu NNaaggaarr GGhhaazziiaabbaadd HEALTH CARE LIMITED Bikaner Thane Theni Q1’FY27 Investor Presentation August 2026 Ludhiana This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. No representation, warranty, guarantee or undertaking, express or implied, is or will be made or any assurance given as to, and no reliance should be placed on, the fairness, #0B50A3 accuracy, completeness or correctness of any information, estimates, projections or opinions contained herein. You must make your own assessment of the relevance, accuracy and adequacy of the information contained in this presentation and must make such independent investigation as you may consider necessary or appropriate. Certain analysis undertaken and represented in this document may constitute an estimate from the Company and may differ from the actual underlying results. R The information provided in this presentation by the Company is for information purposes only. This presentation or any information herein shall not be used, reproduced, copied or duplicated in any form or by any means, or re-circulated, redistributed, passed on, published in any media, website or otherwise disseminated, to any other person, in any form or manner. This presentation does not constitute an offer or invitation or inducement to purchase or sell or subscribe to, any securities of the Company. This M presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document to purchase or sell securities under the #5BCFDE Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 or any other applicable law, as amended from time to time. A The statements contained in this presentation speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to #E7F8FA supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. Neither the Company nor any of its affiliates, its board of directors, its management, advisers or representatives shall have any responsibility or liability whatsoever (in negligence or otherwise) for any loss (direct or indirect) howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. #7F7F7F S The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such revision or changes. D Certain statements made in this presentation may be “forward looking statements” for purposes of laws and regulations of India and other than India. These statements include descriptions regarding the intent, belief or current expectations of the Company or its directors and officers with respect to the results of operations and financial condition, general business plans and strategy, the industry in which the Company operates and the general, business, competitive and regulatory environment of the Company. These statements can be recognized by the use of words such as “expects,” “plans,” “will,” “estimates,” “projects,” or other words of similar meaning. Such forward- looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in such forward-looking statements as a result of various factors and assumptions, including future changes or developments in the Company’s business, its competitive environment, information technology and political, economic, legal, regulatory, environmental and social conditions in India, which the Company believes to be reasonable in light of its operating experience in recent years. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company. The distribution of this presentation in certain jurisdictions may be restricted by law and persons in whose possession this presentation comes should inform themselves about, and observe, any such restrictions. Eyes On The Future AGENDA PERFORMANCE SNAPSHOT BUSINESS UPDATES FINANCIAL PERFORMANCE UPDATE DR. AGARWAL’S HEALTH CARE – AT A GLANCE DR. AGARWAL’S EYE HOSPITAL – AT A GLANCE OVERVIEW OF EYE CARE INDUSTRY PERFORMANCE SNAPSHOT Type Usilampatti We are INDIA’S PRIMARY Financial Overview (Q1’FY27) LARGEST Eye Guduvanchery Care Services ₹614 Cr. ₹177 Cr. ₹55 Cr. Nasaraopet Shahdara Chain Revenue from Operations IndAS EBITDA(1) Profit After Tax 26.0% 25.2% 44.6% Moshi PLUS YoY Growth Rate YoY Growth Rate YoY Growth Rate TERTIARY Operational Overview (Q1’FY27) Sr no Type Branch name 1 EYE CLINIC ZIRAKPUR 2 PRIMARY JANIPUR 304 882K+ 1,057 Trusted Brand Number of Eye Care Facilities(2) Patients Served Doctors 18 91K+ 2,284 Type Facility Additions – Q1’FY27 Surgeries Performed Paramedics PRIMARY Source: Crisil Intelligence Note: As of June 30, 2026 1. EBITDA calculated as Profit Before Tax + Depreciation, Amortisation and Impairment Expense + Finance Costs and Includes Other Income 5 2. As of June 30, 2026; Includes closure of two primary facilities in Janipur (Jammu) and Zirakpur (Punjab) SECONDARY TERTIARY MH – 5 (Wagholi, Moshi, Ulhasnagar, Ahilyanagar, TMH) TN – 3 (Theni, guduvanchery) Delhi – 3 (Faridabad, Shahdara, Nehru Nagar) KA – 2 (Kollam, irinajalakuda) AP (Nasaraopet), J&K (Alamgiri), Punjab (Ludhiana) , RJ (Bikaner), TG – 1 (RC Puram) Type -WISE FACILITIES Count Type 189 1 84 Our Geographic Footprint 52 2 39 PRIMARY 3 38 4 28 5 27 89.9% 10.1% -WISE FACILITIES Count 6 11 SECONDARY 84 7 10 North Jammu & 5 Revenue from Operations Revenue from Operations 30 Kashmir 39 8 8 Chandigarh 38 9 9 1 28 Punjab 8 10 4 4 Haryana 11 11 4 5 Delhi Uttar Pradesh 10 12 3 Rajasthan 8 13 4 9 14 3 15 5 Ghana 7 Uganda 4 1 Kenya 16 5 5 Gujarat 10 Madhya Pradesh 3 West Bengal 1 2 4 4 17 1 18 1 18 11 Rwanda Tanzania 5 West 1 TERTIARY 19 1 East 4 3 38 Orissa 52 285 Maharashtra 14 3 Mozambique 27 1 Telangana 2 1 1 4 New city added` 28 Zambia India International 1 2 4 Andhra Pradesh Mauritius Karnataka 39 4 3 285 19 285 3 3 285 Puducherry Andaman & 19 Madagascar 14 4 2 1 Nicobar Islands 5 5 2 Kerala 9 84 1 1 9 6 1 South 165 7 1 Tamil Nadu 14 states 9 304 8 1 & 5 UTs Countries Sr no Type Branch name 1 EYE CLINIC ZIRAKPUR 304 With a diversified presence across 165 cities, India remains our core focus market 2 PRIMARY JANIPUR Clinical Excellence | Technology-Enabled Precision Care Specialized Surgi [Showing first 8,000 characters — download PDF for full document]